Considering the evidence of simultaneous immunohistochemical expression positive for AMACR and negative for the PSMA antibody, as well as the evidence of [18F]FDG-avid/PSMA-negative PCa on PET imaging, AMACR is a candidate as a pioneer target for novel radiotracers in PCa [64]. Here, AMACR is linked to posterior cortical atrophy.